CoChat

The effect of chronic twice daily exenatide treatment on β‐cell function in new onset type 2 diabetes

Open access
Gastaldelli, Amalia, Brodows, Robert G., D'Alessio, David · 2014 · Clinical Endocrinology
Cited by 24

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Objective: To determine the effect of chronic daily exenatide treatment on β‐cell function in type 2 diabetes (T2DM). Background: Glucagon‐like peptide receptor agonists, such as exenatide, are commonly used to treat patients with T 2 DM. Drugs in this class are insulinotropic but lower blood glucose by multiple mechanisms such that effects on β‐cell function can be difficult to discern by conventional measures. Design: Seventy‐nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5‐ or 10‐μg twice daily, or placebo. All subjects had oral glucose tolerance tests (OGTT) before and after randomization with measurement of plasma glucose, insulin and C‐peptide concentrations. Insulin secretion rates (ISR), peripheral insulin sensitivity (OGIS) and hepatic insulin resistance index (Hep‐IR) were calculated. Results: During the trial, all three groups lost similar, small but significant, amounts of weight. Compared to placebo, 24 weeks of daily high‐ or low‐dose exenatide treatment reduced HbA1c and improved fasting and postprandial hyperglycaemia. Exenatide was associated with improved OGIS and Hep‐IR independent of changes in weight. Plasma insulin levels and ISR during the OGTT did not differ before or after treatment with exenatide or placebo. However, when considered as a function of plasma glucose and insulin sensitivity, both doses of exenatide improved ISR proportionately to the improvement in plasma glucose. The higher dose of exenatide was associated with a significant improvement in β‐cell sensitivity to glucose. Conclusions: These findings demonstrate that in persons with early T2DM, chronic treatment with exenatide enhanced ISR and increased β‐cell sensitivity to glucose. These improvements in β‐cell function were not clearly reflected in plasma insulin and C‐peptide levels, but became apparent when glycemia and insulin sensitivity were accounted for.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cen.12199

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Gastaldelli, A., Brodows, R. G., & D'Alessio, D.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2013-04-11
Volume
80
Issue
4
Pages
545-553
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2042200044
Cited by
24
References
13
FWCI
2.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.